Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPaCE-MT
2024-520213-45-00Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2025
- Modality
- Cell Therapies, Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of MT-302 in Esophagogastric Cancer, sponsored by Amsterdam University Medical Center. Planned start Jul 2025; status: authorised.
02
Drugs
MT-302
03
Conditions
Esophagogastric Cancer
Beyond the preview
Go deeper on 2024-520213-45-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520213-45-00.